

# Ten-year Consolidated Financial Highlights

(₹ in Crores)

Particulars	Financial Year Ended on									
	31.03.2023	31.03.2022	31.03.2021	31.03.2020	31.03.2019	31.03.2018	31.03.2017	31.03.2016	31.03.2015	31.03.2014
Income from Operations	7,283	6,871	5,023	4,621	4,706	3,806	3,163	3,007	2,908	2,632
EBIDTA	1,079	1,720	982	986	967	707	655	578	471	412
Interest	168	102	86	125	183	132	117	117	138	118
Depreciation	310	246	231	185	163	146	123	99	82	89
Profit before Tax	611	1,372	665	676	622	429	416	363	255	206
Share of Profit from Associates	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	14	11
Profit after Tax	545	1,186	523	536	492	333	316	257	206	162
Dividend %	50	70	50	190	100	20	NA	170	110	90
Payout	91	127	44	105	44	10	1	69	52	42
Per Share Dividend (in ₹)	2.50	3.50	2.50	9.50	5.00	1.00	NA	8.50	5.50	4.50
Equity Share	181.25	+++181.25	87.12	++87.12	+43.33	****40.65	****41.06	***41.66	44.30	44.30
Reserve & Surplus	4,739	4,335	3,416	2,892	2,587	1,538	1,321	1,096	972	826
Networth	4,921	4,517	3,515	3,073	2,715	1,655	1,426	1,189	1,016	871
Long term & Short term Borrowings	2,874	2,568	2,492	1,811	2,106	1,921	1,436	1,233	1,068	949
Gross Fixed Assets	6,335	5,083	5,155	3,837	3,362	3,101	2,655	2,081	1,685	1,477
Net Fixed Assets	4,860	3,595	3,592	2,468	2,147	1,998	1,697	1,246	967	826
Capital work-in-progress	1,096	1,346	1,298	1,418	795	436	270	313	193	117
Investments	17	28	64	37	33	47	47	41	139	117
Net Working Capital	1,768	2,088	1,287	1,172	2,039	1,272	1,004	950	893	848
Book Value Per Share (₹)	135.74	124.60	201.75	176.39	313.23	203.62	173.69	142.75	114.73	98.29
EPS (Basic & Diluted) (₹)	15.04	32.71	30.04	++30.77	+60.39	****40.95	****38.45	***30.83	23.24	18.34
EBIDTA/Income from Operations	14.8%	25.0%	19.6%	21.3%	20.5%	18.6%	20.7%	19.2%	16.2%	15.7%
Net Profit Margin %	7.5%	17.3%	10.4%	11.6%	10.5%	8.7%	10.0%	8.5%	7.1%	6.2%
Debt/Equity Ratio	0.58	0.57	0.81	0.68	0.88	1.26	1.10	1.09	1.18	1.20
RONW %	11.5%	29.5%	15.9%	18.5%	22.5%	21.6%	24.2%	23.3%	21.8%	20.0%

Pursuant to the Scheme of Arrangement for Demerger of Pharma Business undertaking wef July 1, 2021, the financials for period prior to July 1, 2021 are inclusive of the Pharma Business undertaking and hence not comparable with the financials for FY 2021-22 and FY 2022-23.

Financials for FY 2021-22 have been suitably recasted to consider the impact of the demerger for Pharma business undertaking. (Please refer to the notes to accounts for more details).

\*\*\* Based on reduction in equity Pursuant to Scheme of Amalgamation between Aarti Industries Limited and Gogri and Sons Investments Private Limited.

Alchemie Leasing and Financing Private Limited, Anushakti Holdings Limited and Anushakti Chemicals and Drugs Limited

\*\*\*\* Based on reduction in equity Pursuant to Scheme of buy-back.

+Based on increased equity post QIP issue

++Based on increased equity post bonus shares issue in the ratio of 1:1 equity share

+++Based on increased equity post bonus shares issue in the ratio of 1:1 equity share & Based on increased equity post QIP issue.

Figures for FY 2016-17 and FY 2015-16 are in the compliance with the Ind AS